| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003403 | American Journal of Ophthalmology | 2011 | 6 Pages |
Abstract
An initial treatment regimen of 3 monthly ranibizumab injections seems effective and safe to treat myopic CNV. Baseline BCVA and myopic CNV location emerged as predictive factors for visual outcome. A need for retreatment was associated with myopic CNV location and prior treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Cristina Calvo-Gonzalez, Juan Reche-Frutos, Juan Donate, Cristina Fernandez-Perez, Julian Garcia-Feijoo,